|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM289416906 |
003 |
DE-627 |
005 |
20231225062513.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2018 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1002/adma.201803217
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0964.xml
|
035 |
|
|
|a (DE-627)NLM289416906
|
035 |
|
|
|a (NLM)30306650
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Zhang, Zhiyun
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Sandwich-Like Fibers/Sponge Composite Combining Chemotherapy and Hemostasis for Efficient Postoperative Prevention of Tumor Recurrence and Metastasis
|
264 |
|
1 |
|c 2018
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 22.03.2019
|
500 |
|
|
|a Date Revised 30.09.2020
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
520 |
|
|
|a Intraoperative bleeding is an essential factor leading to the earliest recurrence and tumor metastasis frequently seen after resection of solid tumors. Local drug delivery implants show the unique advantages on postoperative cancer therapy. Herein, a sandwich-like cisplatin-loaded fibers/sponge composite (CFSC) combining chemotherapy and hemostasis is constructed. The obtained implantable CFSC is able to simultaneously stop bleeding and absorb disseminated tumor cells after tumor resection. More importantly, sustained released cisplatin can kill local residual tumor cells as well as those concentrated in the CFSC, which significantly inhibits local tumor recurrence and distant tumor metastasis on the subcutaneous postoperative recurrence model and metastasis models. This dual functional implant strategy with low toxicity to healthy organs may inspire new aspects for efficient postoperative cancer therapy
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a chemotherapy
|
650 |
|
4 |
|a hemostasis
|
650 |
|
4 |
|a implants
|
650 |
|
4 |
|a postoperative cancer therapy
|
650 |
|
4 |
|a recurrence and metastasis
|
650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
650 |
|
7 |
|a Drug Carriers
|2 NLM
|
650 |
|
7 |
|a Cisplatin
|2 NLM
|
650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
700 |
1 |
|
|a Kuang, Gaizhen
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zong, Shan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Liu, Shi
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Xiao, Haihua
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Xuesi
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhou, Dongfang
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Huang, Yubin
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 30(2018), 49 vom: 15. Dez., Seite e1803217
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
773 |
1 |
8 |
|g volume:30
|g year:2018
|g number:49
|g day:15
|g month:12
|g pages:e1803217
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201803217
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 30
|j 2018
|e 49
|b 15
|c 12
|h e1803217
|